

## REFERENCES

- Abdel-Nabi, H. H., Doerr, R. J., Chan, H. W., Farrell, E., Evans, N. H., Spaulding, M. B., et al. (1992). Safety and role of repeated administrations of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the postoperative follow-up of colorectal carcinoma patients. *Journal of Nuclear Medicine*, *33*, 14-22.
- Abdel-Nabi, H. H., Levine, G., Lamki, L. M., Murray, J. L., Tauxe, W. N., Shah, A. N., et al. (1990). Colorectal carcinoma metastases: detection with In-111-labeled monoclonal antibody CCR 086. *Radiology*, *176*, 117-122.
- Akselband, Y., Moen, P. T. Jr., & Mcgrath, P. (2003). Isolation of rare isotype switch variants in hybridoma cell lines using an agarose gel microdrop-based protein secretion assay. *ASSAY and Drug Development Technologies*, *1*, 619-626.
- Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascon, P. (2003). Mechanisms of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. *Advances in Experimental Medicine and Biology*, *532*, 253-268.
- Almagro, J. C., & Fransson, J. (2008). Humanization of antibodies. *Frontiers in Bioscience*, *13*, 1619-1633.
- Aybay, C., & Imir, T. (2000). Development of a rapid, single-step procedure using protein G affinity chromatography to deplete fetal calf serum of its IgG and to isolate murine IgG1 monoclonal antibodies from supernatants of hybridoma cells. *Journal of Immunological Methods*, *233*, 77-81.
- Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A., et al. (2003). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *The New England Journal of Medicine*, *348*, 601-608.
- Bailey, C. G., Tait, S. A., & Sunstrom, N. A. (2002). High-throughput clonal selection of recombinant CHO cells using a dominant selectable and amplifiable metallothionein-GFP fusion protein. *Biotechnology and Bioengineering*, *80*, 670-676.
- Barnes, L. M., Bentley, C. M., & Dickson, A. J. (2001). Characterization of the stability of recombinant protein production in the GS-NS0 expression system. *Biotechnology and Bioengineering*, *73*, 261-270.
- Barnes, L. M., & Dickson, A. J. (2006). Mammalian cell factories for efficient and stable protein expression. *Current Opinion in Biotechnology*, *17*, 381-386.

Barnes, L. M., Moy, N., & Dickson, A. J. (2006). Phenotypic variation during cloning procedures: Analysis of the growth behavior of clonal cell lines. *Biotechnology and Bioengineering*, 94, 530-537.

Bengtén, E., Wilson, M., Miller, N., Clem, L. W., Pilstrom, L., & Warr, G. W. (2000). Immunoglobulin isotypes: structure, function, and genetics. *Current Topics in Microbiology and Immunology*, 248, 189-219.

Benton, T., Chen, M., Fox, B., King, D., Crombie, R., Thomas, T.C., et al. (2002). The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein. *Cytotechnology*, 38, 43-46.

Berberich, R., Hennes, P., & Alexander, C. (1992). The detection of inflammation and the formation of HAMA following the administration of monoclonal antibody BW 250/183. *Nuklearmedizin*, 31, 70-73.

Boillot, A., Capellier, G., Racadot, E., Wijdenes, J., Herve, P., & Barale, F. (1995). Pilot clinical trial of an anti-TNF $\alpha$  monoclonal antibody for the treatment of septic shock. *Clinical Intensive Care*, 6, 52-56.

Borjesson, P. K., Postema, E. J., Roos, J. C., Colnot, D. R., Marres, H. A., Van Schie, M.H., et al. (2003). Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. *Clinical Cancer Research*, 9, 3961-3972.

Borth, N., Zeyda, M., & Katinger, H. (2000). Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. *Biotechnology and Bioengineering*, 71, 266-273.

Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984). Production of functional chimaeric mouse/human antibody. *Nature*, 312, 643-646.

Bowen, J. D., Petersdorf, S. H., Richards, T. L., Maravilla, K. R., Dale, D. C., Price, T. H., et al. (1998). Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. *Clinical Pharmacology & Therapeutics*, 64, 339-346.

Browne, S. M., & Al-Rubeai, M. (2007). Selection methods for high-producing mammalian cell lines. *Trends in Biotechnology*, 25, 425-432.

Buist, M. R., Kenemans, P., Van Kamp, G. J., & Haisma, H. J. (1995). Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. *Cancer Immunology, Immunotherapy*, *40*, 24-30.

Butler, M. (2005). Animal cell cultures: Recent achievements and perspectives in the production of biopharmaceuticals. *Applied Microbiology and Biotechnology*, *68*, 283-291.

Cacciatore, J. J., Chasin, L. A., & Leonard, E. F. (2010). Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. *Biotechnology Advances*, *28*, 673-681.

Caron, A. W., Nicolas, C., Gaillet, B., Ba, I., Pinard, M., Garnier, A., et al. (2009). Fluorescent labeling in semi-solid medium for selection of mammalian cells secreting high-levels of recombinant proteins. *BMC Biotechnology*, *9*, <http://www.biomedcentral.com/1472-6750/9/42>.

Carpenter, P. A., Appelbaum, F. R., Corey, L., Deeg, H. J., Doney, K., Gooley, T., et al. (2002). A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host-disease. *Blood*, *99*, 2712-2719.

Carroll, S., & Al-Rubeai, M. (2004). The selection of high-producing cell lines using flow cytometry and cell sorting. *Expert Opinion on Biological Therapy*, *4*, 1821-1829.

Carroll, S., & Al-Rubeai, M. (2005). ACSF labelling and magnetic cell separation: A rapid method of separating antibody secreting cells from non-secreting cells. *Journal of Immunological Methods*, *296*, 171-178.

Cherng, J. Y., Schuurmans-Nieuwenbroek, N. M. E., Jiskoot, W., Talsma, H., Zuidam, N. J., Hennink, W. E., et al. (1999). Effect of DNA topology on the transfection efficiency of poly((2-dimethylamino)ethyl methacrylate)-plasmid complexes. *Journal of Controlled Release*, *60*, 343-353.

Choy, E. H., Schantz, A., Pitzalis, C., Kingsley, G. H., & Panayi, G. S. (1998). The pharmacokinetics and human anti-mouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody. *British Journal of Rheumatology*, *37*, 801-802.

Clark, M. (2000). Antibody humanization: a case of the 'Emperor's new clothes'?. *Immunology Today*, *21*, 397-402.

Colnot, D. R., Quak, J. J., Roos, J. C., van Lingen, A., Wilhelm, A. J., van Kamp, G. J., et al. (2000). Phase I therapy study of <sup>186</sup>Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. *Journal of Nuclear Medicine*, *41*, 1999-2010.

Colnot, D. R., Roos, J. C., de Bree, R., Wilhelm, A. J., Kummer, J. A., Hanft, G., et al. (2003). Safety, biodistribution, pharmacokinetics, and immunogenicity of <sup>99m</sup>Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. *Cancer Immunology, Immunotherapy*, *52*, 576-582.

Croce, C. M., Linnenbach, A., Hall, W., Steplewski, Z., & Koprowski, H. (1980). Production of human hybridomas secreting antibodies to measles virus. *Nature*, *288*, 488-489.

Crombet, T., Torres, O., Neninger, E., Catala, M., Rodriguez, N., Ramos, M., et al. (2001). Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. *Cancer Biotherapy and Radiopharmaceuticals*, *16*, 93-102.

Cui, Z., Baizer, L., & Mumper, R. J. (2003). Intradermal immunization with novel plasmid DNA-coated nanoparticles via needle-free injection device. *Journal of Biotechnology*, *102*, 105-115.

Czuczman, M. S., Straus, D. J., Divgi, C. R., Graham, M., Garin-Chesa, P., Finn, R., et al. (1993). Phase I dose-escalation trial of iodine <sup>131</sup>-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, *11*, 2021-2029.

De Jager, R., Abdel-Nabi, H., Serafini, A., Pecking, A., Klein, J. L., & Hanna Jr., M. G. (1993). Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. *Seminars in Nuclear Medicine*, *23*, 165-179.

Demaria, C. T., Cairns, V., Schwarz, C., Zhang, J., Guerin, M., Zuena, E., et al. (2007). Accelerated clone selection for recombinant CHO cells using a FACS-based high-throughput screen. *Biotechnology Progress*, *23*, 465-472.

DeNardo, S. J., Kramer, E. L., O'Donnell, R. T., Richman, C. M., Salako, Q. A., Shen, S., et al. (1997). Radioimmunotherapy for breast cancer using indium-111/yttrium-90 bre-3: results of a phase I clinical trial. *Journal of Nuclear Medicine*, *38*, 1180-1185.

Dharshanan, S., Chong, H., Cheah, S. H., Zamrod, Z., & Nazlee, K. (2011a). Rapid automated selection of mammalian cell line secreting high level of humanized monoclonal antibody using ClonePix FL system and the correlation between exterior median intensity and antibody productivity. *Electronic Journal of Biotechnology*, *14*, doi: 10.2225/vol14-issue2-fulltext-7.

Dharshanan, S., Chong, H., Cheah, S. H., & Zamrod, Z. (2011b). Application of cytotechnology techniques: A case study for production, purification and characterization of humanized antibody secreted by NS0 transfectoma. *Asia-Pacific Journal of Molecular Biology and Biotechnology*, *19*, 63-71.

Edwards, P. A. W., Smith, C. M., Neville, A. M., & O'Hare, M. (1982). A human-human hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. *European Journal of Immunology*, *12*, 641-648.

Endo, K. (1990). Use of radiolabeled monoclonal antibodies for diagnostic imaging. *Nippon Igaku Hoshasen Gakkai Zasshi*, *50*, 901-909.

Even, M. S., Sandusky, C. B., & Barnard, N. D. (2006). Serum-free hybridoma culture: ethical, scientific and safety considerations. *Trends in Biotechnology*, *24*, 105-108.

Even, M. S., Sandusky, C. B., Barnard, N. D., Mistry, J. (2007). Development of a novel ELISA for human insulin using monoclonal antibodies produced in serum-free cell culture medium. *Clinical Biochemistry*, *40*, 98-103.

Ewenstein, B. M., Hoots, W. K., Lusher, J. M., DiMichele, D., White, G. C., Adelman, B., et al. (2000). Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. *Haematologica*, *85*, 35-39.

Falkner, E., Appl, H., Eder, C., Losert, U. M., Schöffl, H., & Pfaller, W. (2006). Serum free cell culture: The free access online database. *Toxicology in Vitro*, *20*, 395-400.

Ferguson, K. M. (2004). Active and inactive conformations of the epidermal growth factor receptor. *Biochemical Society Transactions*, *32*, 742-745

Foote, J., & Winter, G. (1992). Antibody framework residues affecting the conformation of the hypervariable loops. *Journal of Molecular Biology*, *224*, 487-499.

Frodin, J. E., Lefvert, A. K., & Mellstedt, H. (1992). The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. *Cell Biophysics*, *21*, 153-165.

Frontiera, M., Murray, J. L., Lamki, L., Thomas, J., Satterlee, W., Schmelter, R., et al. (1989). Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. *Clinical Nuclear Medicine*, *14*, 357-366.

Frykman, S. & Srienc, F. (1988). Quantitating secretion rates of individual cells: Design of secretion assays. *Biotechnology and Bioengineering*, *59*, 214-226.

Gavilondo, J. V., & Larrick J. W. (2000). Antibody engineering at the millennium. *Biotechniques*, *29*, 128-145.

Ghosh, S., Goldin, E., Gordon, H. F., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., et al. (2003). Natalizumab for active Crohn's disease. *New England Journal of Medicine*, *348*, 24-32.

Goldman-Leikin, R. E., Kaplan, E. H., Zimmer, A. M., Kazikiewicz, J., Manzel, L. J., & Rosen, S. T. (1988). Long-term persistence of human anti-murine antibody responses following radioimmunoassay and radioimmunotherapy of cutaneous T-cell lymphoma patients using <sup>131</sup>I-T101. *Experimental Hematology*, *16*, 861-864.

Goldsby, R. A., Kindt, T. J., Kuby, J., Osborne, B. A. (Eds.) (2002). *Immunology*. Hampshire: W. H. Freeman.

Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., et al. (2001). Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer. *Journal of Clinical Oncology*, *19*, 843-850.

Green, L. L. (1999). Antibody engineering via genetic engineering of a mouse: Xeno-Mouse strains are a vehicle for the facile generation of therapeutics human monoclonal antibodies. *Journal of Immunological Methods*, *231*, 11-23.

Greenaway, S., Henniker, A. J., Walsh, M., & Bradstock, K. F. (1994). A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia. *Leukemia and Lymphoma*, *13*, 323-331.

Grunfeld, H., & Moore, P. (1997). Reduction of bovine immunoglobulin contamination from monoclonal antibodies by SOURCE 15PHE chromatography. *Journal of Immunological Methods*, *201*, 233-241.

Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D. J., et al. (2000). Targeted antiangiogenic therapy for cancer using *Vitaxin*: a humanized monoclonal antibody to the integrin  $\alpha V\beta 3$ . *Clinical Cancer Research*, 6, 3056-3061.

Hammill, L., Welles, J., & Carson, G. (2000). The gel microdrop secretion assay: Identification of a low productivity subpopulation arising during the production of human antibody in CHO cells. *Cytotechnology*, 34, 27-37.

Hammond, E. A., Yowell, R. L., Greenwood, J., Hartung, L., Renlund, D., & Wittwer, C. (1993). Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization. *Transplantation*, 55, 1061-1063.

Hanania, E. G., Fieck, A., Stevens, J., Bodzin, L. J., Palsson, B. O., & Koller, M. R. (2005). Automated in situ measurement of cell-specific antibody secretion and laser-mediated purification for rapid cloning of highly-secreting producers. *Biotechnology and Bioengineering*, 91, 872-876.

Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., et al. (1995). A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. *European Journal of Cancer*, 31A, 261-267.

Hertel, A., Baum, R. P., Lorenz, M., Baew-Christow, T., Encke, A., & Hor, G. (1990). Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA. *British Journal of Cancer. Supplement*, 10, 34-36.

Hinkula, J., Bratt, G., Gilljam, G., Nordlund, S., Broliden, P. A., Holmberg, V., et al. (1994). Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. *Journal of Acquired Immune Deficiency Syndromes*, 7, 940-951.

Hird, V., Verhoeyen, M., Badley, R. A., Price, D., Snook, D., Kosmas, C., et al. (1991). Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. *British Journal of Cancer*, 64, 911-914.

Hnatowich, D. J., Rusekowski, M., Siebecker, D. A., Gionet, M., Mardirossian, G., Bushe, H. S., et al. (1992). Pharmacokinetics of indium-111 labeled 10-3D2 antibreast-tumor antibody in patients. *Journal of Nuclear Biology & Medicine*, 36, 7-13.

Hober, S., Nord, K., & Linhult, M. (2007). Protein A chromatography for antibody purification. *Journal of Chromatography B*, 848, 40-47.

Hong, K., Presta, L. G., Lu, Y., Penn, A., Adams, C., Chuntharapai, A., et al. (2001). Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. *Journal of Immunological Methods*, 294, 189-197.

Horneff, G., Winkler, T., Kalden, J. R., Emmrich, F., & Burmester, G. R. (1991). Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. *Clinical Immunology and Immunopathology*, 59, 89-103.

Huse, K., Bohme, H. J., & Scholz, G. H. (2002). Purification of antibodies by affinity chromatography. *Journal of Biochemical and Biophysical Methods*, 51, 217-231.

Hwang, W. Y. K., & Foote, J. (2005). Immunogenicity of engineered antibodies. *Methods*, 36, 3-10.

Iznaga-Escobar, N., Ramos-Suzarte, M., Morales-Morales, A., Torres-Arocha, L., Rodriguez-Mesa, N., & Perez-Rodriguez, R. (2004). <sup>99m</sup>Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: Pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization. *Methods and Findings in Experimental and Clinical Pharmacology*, 26, 687-696.

Jacobsen, L. B., Calvin, S. A., & Lobenhofer, E. D. (2009). Transcriptional effects of transfection: The potential for misinterpretation of gene expression data generated from transiently transfected cells. *Biotechniques*, 47, 617-624.

Jiskoot, W., Hertrooij, V. J., Hoven, A. M., Gebbinck, J. W. K., Groot, T. V. V. G., Crommelin, D. J., et al. (1991). Preparation of clinical grade monoclonal antibodies from serum-containing cell culture supernatants. *Journal of Immunological Methods*, 138, 273-283.

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature*, 321, 522-525.

Jurcic, J. G., DeBlasio, T., Dumont, L., Yao, T., & Scheinberg, D. A. (2000). Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. *Clinical Cancer Research*, 6, 372-380.

Kacmar, J., & Srienc, F. (2005). Dynamics of single cell property distributions in Chinese hamster ovary cell cultures monitored and controlled with automated flow cytometry. *Journal of Biotechnology*, 120, 410-420.



Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001). Pivotal study of Bexxar (Iodine I-131 Tositumomab) for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. *Journal of Clinical Oncology*, *19*, 3918-3928.

Kannan, T. P., Ali, Q. A., Abdullah, S. F., & Ahmad, A. (2009). Evaluation of Tualang honey as a supplement to fetal bovine serum in cell culture. *Food and Chemical Toxicology*, *47*, 1696-1702.

Karpas, A., Fischer, P., & Swirsky, D. (1982). Human plasmacytoma with an unusual karyotype growing in vitro and producing light-chain immunoglobulin. *Lancet*, *1*, 931-933.

Keenan, J., Pearson, D., & Clynes, M. (2006). The role of recombinant proteins in the development of serum-free media. *Cytotechnology*, *50*, 49-56.

Khazaeli, M. B., Conry, R. M., & Lobuglio A. F. (1994). Human immune response to monoclonal antibodies. *Journal of Immunotherapy*, *15*, 42-52.

Kim, M., O'Callahan, P. M., Droms, K. A., & James, D. C. (2011). A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies. *Biotechnology and Bioengineering*, doi: 10.1002/bit.23189.

Kim, N. S., Byun, T. H., & Lee, G. M. (2001). Key determinants in the occurrence of clonal variation in humanized antibody expression of CHO cells during dihydrofolate reductase mediated gene amplification. *Biotechnology Progress*, *17*, 69-75.

Kohler G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody with predefined specificity. *Nature*, *256*, 495-497.

Koller, M. R., Hanania, E. G., Stevens, J., Einfeld, T. M., Sasaki, G. C., Fieck, A., et al. (2004). High-throughput laser-mediated in situ cell purification with high purity and yield. *Cytometry Part A*, *61A*, 153-161.

Kozbor, D., & Roder, J. C. (1981). Requirements for the establishment of high-titered human monoclonal antibodies using the Epstein-Barr virus technique. *Journal of Immunology*, *127*, 1275-1280.

Kramer, E. L., Liebes, L., Wasserheit, C., Noz, M. E., Blank, E. W., Zabalegui, A., et al. (1998). Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. *Clinical Cancer Research*, *4*, 1679-1688.

Kreiss, P., Cameron, B., Rangara, R., Mailhe, P., Aguerre, C. O., Airiau, M., et al. (1999). Plasmid size does not affect the physiochemical properties of lipoplexes but modulates gene transfer efficiency. *Nucleic Acids Research*, *27*, 3792-3798.

Kwaks, T. H. J., & Otte, A. P. (2006). Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells. *Trends in Biotechnology*, doi: 10.1016/j.tibtech.2006.01.007.

Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*, *227*, 680-685.

Lamers, C. H., Gratama, J. W., Warnaar, S. O., Stoter, G., & Bolhuis, R. L. (1995). Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytotoxicity by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. *International Journal of Cancer*, *60*, 450-457.

Le Doussal, J. M., Chetanneau, A., Gruaz-Guyon, A., Martin, M., Gautherot, E., Lehur, P. A., et al. (1993). Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. *Journal of Nuclear Medicine*, *34*, 1662-1671.

Lee, C., Ly, C., Sauerwald, T., Kelly, T., & Moore, G. (2006). High-throughput screening of cell lines expressing monoclonal antibodies. *Bioprocess International*, *4*, 32-35.

Legouffe, E., Liautard, J., Gaillard, J. P., Rossi, J. F., Wijdenes, J., Bataille, R., et al. (1994). Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. *Clinical and Experimental Immunology*, *98*, 323-329.

Levy, R., & Miller, R. (1983). Biological and clinical implications of hybridomas: tumor therapy with monoclonal antibodies. *Annual Review of Medicine*, *14*, 1352-1359.

Li, J., Menzel, C., Meier, D., Zhang, C., Dubel, S., & Jostock, T. (2007). A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. *Journal of Immunological Methods*, *318*, 113-124.

Li, G., Xie, L., Zhou, G., Fu, H., Zhou, J., & Sun, Q. (2002). A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients. *Chinese Medical Journal (English Edition)*, *115*, 567-570.

Luiten, R. M., Warnaar, S. O., Sanborn, D., Lamers, C. H., Bolhuis, R. L., Litvinov, S. V., et al. (1997). Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. *Journal of Immunotherapy*, *20*, 496-504.

Maher, V. E., Drukman, S. J., Kinders, R. J., Hunter, R. E., Jennings, J., Brigham, C., et al. (1992). Human antibody response to the intravenous and intraperitoneal administration of the F(ab')<sub>2</sub> fragment of the OC125 murine monoclonal antibody. *Journal of Immunotherapy*, *11*, 56-66.

Mann, C. J. (2007). Rapid isolation of antigen-specific clones from hybridoma fusions. *Nature Methods*, *4*, i-ii.

Margalit, H., Spouge, J. L., Cornette, J. L., Cease, K. B., Delisi, C., & Berzofsky, J. A. (1987). Prediction of immunodominant helper T cell antigenic sites from the primary sequence. *Journal of Immunology*, *138*, 2213-2229.

Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., et al. (2001). Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data. *Journal of Clinical Oncology*, *19*, 851-856.

Mateo, C., Moreno, E., Amour, K., Lombardero, J., Harris, W., & Perez, R. (1997). Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. *Immunotechnology*, *3*, 71-81.

Mateo, C., Lombardero, J., Moreno, E., Morales, A., Bombino, G., Coloma, J., et al. (2000). Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. *Hybridoma*, *19*, 463-471.

Meng, G. Y., Liang, J., Wong, W. L., & Chisholm, V. (2000). Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells. *Gene*, *242*, 201-207.

Moore, P., & Clayton, J. (2003). To affinity and beyond. *Nature*, *426*, 725-731.

Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984). Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. *Proceedings of the National Academy of Sciences of the United States of America*, *81*, 6851-6855.

Murray, J. L., Cunningham, J. E., Brewer, H., Mujoo, K., Zukiwski, A. A., & Podoloff, D. A., et al. (1994). Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. *Journal of Clinical Oncology*, *12*, 184-193.

Muxi, A., Pons, F., Herranz, R., Novell, F., Fernandez, R., Filella, X., et al. (1993). Radioimmunosciintigraphy of colorectal carcinoma with a <sup>111</sup>In-labelled anti-TAG-72 monoclonal antibody. *Nuclear Medicine Communications*, *14*, 775-787.

Nayak, A., Casale, T., Miller, S. D., Condemi, J., McAlary, M., Fowler-Taylor, A., et al. (2003). Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. *Allergy and Asthma Proceedings*, *24*, 323-329.

Nechansky, A. (2010). HAHA-nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. *Journal of Pharmaceutical and Biomedical Analysis*, *50*, 252-254.

O'Donnell, R. T., Shen, S., Denardo, S. J., Wun, T., Kukis, D. L., Goldstein, D. S., et al. (2000). A phase I study of 90Y-2ITBAD-Lym-1 in patients with non-Hodgkin's lymphoma. *Anticancer Research*, *20*, 3647-3655.

Olsson, L., & Kaplan, H. S. (1980). Human hybridomas producing monoclonal antibodies of predefined antigenic specificity. *Proceedings of the National Academy of Sciences of the United States of America*, *77*, 5429-5434.

Padlan, E. A. (1991). A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. *Molecular Immunology*, *28*, 489-498.

Piro, L. D., White, C. A., Grillo-Lopez, A. J., Janakiraman, N., Saven, A., Beck, T. M., et al. (1999). Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. *Annals of Oncology*, *10*, 655-661.

Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., et al. (2001). A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti- $\alpha_v\beta_3$ ) antibody in patients with metastatic cancer. *Cancer Biotherapy and Radiopharmaceuticals*, *16*, 125-132.

Presta, L. G. (2006). Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. *Advanced Drug Delivery Reviews*, *58*, 640-656.

Ramos, M., Rodriguez, N., Oliva, J. P., Iznaga-Escobar, N., Perena, A., Torres, L., et al. (2003). Study of *in vivo* examination of tumors of epithelial origin for the monoclonal antibodies ior C5, ior egf/r3 and humanized hr3, by using immunogammgraphy technique. *Nucleus*, 33, 54-63.

Ramos-Suzarte, M., Pintado, A. P., Mesa, N. R., Oliva, J. P., Iznaga-Escobar, N., Aroche, L. T., et al. (2007). Diagnostic efficacy and safety of <sup>99m</sup>Tc-Labeled monoclonal antibody Ior c5 in patients with colorectal and anal carcinomas. *Cancer Biology and Therapy*, 6, 22-29.

Rasmussen, L. K., Larsen, Y. B., & Højrup, P. (2005). Characterization of different cell culture media for expression of recombinant antibodies in mammalian cells: Presence of contaminating bovine antibodies. *Protein Expression and Purification*, 41, 373-377.

Reichert, J. M., & Valge-Archer, V. E. (2007). Development trends for monoclonal antibody cancer therapeutics. *Nature Reviews*, 6, 349-356.

Remaut, K., Sanders, N. N., Fayazpour, F., Demeester, J., De Smedt, S. C. (2006). Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes. *Journal of Controlled Release*, 115, 335-343.

Renner, C., Hartmann, F., Jung, W., Deisting, C., Juwana, M., & Pfreundschuh, M. (2000). Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody. *Cancer Immunology, Immunotherapy*, 49, 173-180.

Richman, C. M., DeNardo, S. J., O'Grady, L. F., & DeNardo, G. L. (1995). Radioimmunotherapy for breast cancer using escalating fractionated doses of <sup>131</sup>I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. *Cancer Research*, 55, 5916s-5920s.

Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988). Reshaping human antibodies for therapy. *Nature*, 332, 323-327.

Riva, P., Marangolo, M., Lazzari, S., Agostini, M., Sarti, G., Moscatelli, G., et al. (1989). Locoregional immunotherapy of human ovarian cancer: preliminary results. *International Journal of Radiation Applications and Instrumentation Part B*, 16, 659-666.

Roitt, I. M. (1993). OKT3: immunology, production, purification and pharmacokinetics. *Clinical Transplantation*, 7, 367-373.

Roque-Navarro, L., Mateo, C., Lombardero, J., Mustelier, G., Fernandez, A., Sosa, K., et al. (2003). Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. *Hybridoma and Hybridomics*, *22*, 245-257.

Roytrakul, S., Eurwilaichitr, L., Suprasongsin, C., & Panyim, S. (2001). A rapid and simple method for construction and expression of a synthetic human growth hormone gene in *Escherichia coli*. *Journal of Biochemistry and Molecular Biology*, *34*, 502-508.

Saleh, M. N., Khazaeli, M. B., Grizzle, W. E., Wheeler, R. H., Lawson, S., Liu, T., et al. (1993). A Phase I Clinical Trial of Murine Monoclonal Antibody D612 in Patients with Metastatic Gastrointestinal Cancer. *Cancer Research*, *53*, 4555-4562.

Sambrook, J., & Russell, D. W. (Eds.) (2001). *Molecular Cloning: A laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Sawada, T., Nishihara, T., Yamamoto, A., Teraoka, H., Yamashita, Y., Okamura, T., et al. (1999). Preoperative clinical radioimmuno-detection of pancreatic cancer by 111 in-labeled chimeric monoclonal antibody Nd2. *Japanese Journal of Cancer Research*, *90*, 1179-1186.

Schulz, G., Buchler, M., Muhrer, K. H., Klapdor, R., Kubel, R., Harthus, H. P., et al. (1988). Immunotherapy of pancreatic cancer with monoclonal antibody BW494. *International Journal of Cancer – Supplement*, *2*, 89-94.

Schwartz, M. A., Lovett, D. R., Redner, A., Finn, R. D., Graham, M. C., Divgi, C. R., et al. (1993). Dose-escalation trial of M195 labelled with iodine 131 for cytorreduction and marrow ablation in relapsed or refractory myeloid leukemias. *Journal of Clinical Oncology*, *11*, 294-303.

Serafini, A. N., Klein, J. L., Wolff, B. G., Baum, R., Chetanneau, A., Pecking, A., et al. (1998). Radioimmuno-scintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: results of pivotal, Phase III multicenter studies. *Journal of Clinical Oncology*, *16*, 1777-1787.

Seth, G., McIvor, R. S., & Hu, W. S. (2006). 17 $\beta$ -Hydroxysteroid dehydrogenase type 7 (Hsd17b7) reverts cholesterol auxotrophy in NS0 cells. *Journal of Biotechnology*, *121*, 241-252.

Shan, D., Ledbetter, J. A., & Press, O. W. (2000). Signalling events involved in anti-CD20-induced apoptosis of malignant human B cells. *Cancer Immunology, Immunotherapy*, *48*, 673-683.

Sharma, S. K., Bagshawe, K. D., Melton, R. G., & Sherwood, R. F. (1992). Human Immune Response to Monoclonal Antibody-Enzyme Conjugates in ADEPT Pilot Clinical Trial. *Cell Biophysics*, *21*, 109-120.

Shield, C. F., Jacobs, R. J., Wyant, S., & Das, A. (1996). A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. *American Journal of Kidney Diseases*, *27*, 855-864.

Solano, M. E., Perera, A., Batista, J. F., Candebat, Z., Jacomino, I., Hierro, M., et al. (2003). Immunoscintigraphic diagnosis of ovarian cancer with Tc-99m labeled MAb ior-C5; first clinical results. *World Journal of Nuclear Medicine*, *2*, 30-36

Staszewski, R. (1990). Murphy's law of limiting dilution cloning. *Statistics in Medicine*, *9*, 457-461.

Steffens, M. G., Boerman, O. C., Oosterwijk-Wakka, J. C., Oosterhof, G. O., Witjes, J. A., Koenders, E. B., et al. (1997). Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. *Journal of Clinical Oncology*, *15*, 1529-1537.

Steinitz, M., Klein, G., Koskimies, S., & Mäkela, O. (1977). EB virus-induced B lymphocyte cell lines producing specific antibody. *Nature*, *269*, 420-422.

Stern, M., & Herrmann, R. (2005). Overview of monoclonal antibodies in cancer therapy: present and promise. *Critical Reviews in Oncology/Hematology*, *54*, 11-29.

Stuchbury, G., & Münch, G. (2010). Optimizing the generation of stable neuronal cell lines via pre-transfection restriction enzyme digestion of plasmid DNA. *Cytotechnology*, *62*, 189-194.

Swinnen, K., Krul, A., Goidsenhoven, I. V., Tichelt, N. V., Roosen, A., & Houdt, K. V. (2007). Performance comparison of protein A affinity resins for the purification of monoclonal antibodies. *Journal of Chromatography B*, *848*, 97-107.

Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., & Honda, M. (1992). Monoclonal antibody-drug conjugate therapy for patients with colorectal cancer. *Journal of Experimental Medicine*, *168*, 371-374.

Tcheng, J. E., Kereiakes, D. J., Lincoff, A. M., George, B. S., Kleiman, N. S., Sane, D. C., et al. (2001). Abciximab readministration: results of the ReoPro readministration registry. *Circulation*, *104*, 870-875.

Tejuca, M., Díaz, I., Figueredo, R., Roque, L., Pazos, F., Martinez, D., et al. (2004). Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line. *International Immunopharmacology*, 4, 731-744.

Thompson, K. M. (1988). Human monoclonal antibodies. *Immunology Today*, 9, 113-117.

Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., et al. (2003). Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. *Journal of Clinical Oncology*, 21, 211-222.

Tsurushita, N., Hinton, P. R., & Kumar, S. (2005). Design of humanized antibodies: From anti-Tac to Zenapax. *Methods*, 36, 69-83.

Uckun, F. M., Messinger, Y., Chen, C. L., O'Neill, K., Myers, D. E., Goldman, F., et al. (1999). Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD-19 directed tyrosine kinase inhibitor. *Clinical Cancer Research*, 5, 3906-3913.

Underwood, A. P., & Bean, P. A. (1988). Hazards of the limiting-dilution method of cloning hybridomas. *Journal of Immunological Methods*, 107, 119-128.

Valk, J. V. D., Mellor, D., Brands, R., Fischer, R., Gruber, F., Gstraunthaler, G., et al. (2004). The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. *Toxicology in Vitro*, 18, 1-12.

Valk, J. V. D., Brunner, D., De Smet, K., Svenningsen, Å. F., Honegger, P., Knudsen, L. E., et al. (2010). Optimization of chemically defined cell culture media – Replacing fetal bovine serum in mammalian in vitro methods. *Toxicology in Vitro*, 24, 1053-1063.

Van Zanten-Przybysz, I., Molthoff, C., Gebbinck, J. K., von Mensdorff-Pouilly, S., Verstraeten, R., Kenemans, P., et al. (2002). Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. *Journal of Cancer Research and Clinical Oncology*, 128, 484-492.

Varga, Z., de Mulder, P., Kruit, W., Hegele, A., Hofmann, R., Lamers, C., et al. (2003). A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. *Folia Biologica (Prague)*, 49, 74-77.



Vazquez, A. M., Tormo, B. R., Velandia, A., Giscombe, R., Ansotegui, I., et al. (1992). Characterization of the colorectal antigen ior C2. *Hybridoma*, *11*, 245-256.

Vazquez, A. M., Tormo, B., Velandia, A., Gomez, C. A., Alfonso, M., Giscombe, R., et al. (1993). Characterization of the colorectal antigen IOR C2.II. *Year in Immunology*, *7*, 137-145.

Vazquez, A. M., Tormo, B. R., Alfonso, M., Velandia, A., Fernandez, L. E., Giscombe, R., et al. (1995). Characterization of ior C5 colorectal tumor associated antigen. *Immunologia*, *14*, 130-132.

Von Groll, A., Levin, Y., Barbosa, M. C., Ravazzolo, A. P. (2006). Linear DNA low efficiency transfection by liposome can be improved by the use of cationic lipid as charge neutralizer. *Biotechnology Progress*, *22*, 1220-1224.

Vose, J. M., Colcher, D., Gobar, L., Bierman, P. J., Augustine, S., Tempero, M., et al. (2000). Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. *Leukemia and Lymphoma*, *38*, 91-101.

Watts, M. J., Wisdom, N. M., Tyrrell, D. A., Hale, G., & Connor, S. E. (1995). Low immunogenicity of therapeutic rat CD45 antibodies when used for pre-treatment of donor organs for transplantation. *Therapeutic Immunology*, *2*, 23-29.

Wegener, W. A., Petrelli, N., Serafini, A., & Goldenberg, D. M. (2000). Safety and efficacy of arcitumomab imaging in colorectal cancer after repeated administration. *Journal of Nuclear Medicine*, *41*, 1016-1020.

Wessman, S. J., & Levings, R. L. (1999). Benefits and risks due to animal serum used in cell culture production. *Developments in Biological Standardization*, *99*, 3-8.

Whitford, W. (2003). NS0 Serum-Free Culture and Applications. *BioProcess International*, *1*, 36-47.

Winzelberg, G. G., Grossman, S. J., Rizk, S., Joyce, J. M., Hill, J. B., Atkinson, D. P., et al. (1992). Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response. *Cancer*, *69*, 1656-1663.

Wong, J. Y., Williams, L. E., Yamauchi, D. M., Odom-Maryon, T., Esteban, J. M., Neumaier, M., et al. (1995). Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. *Cancer Research*, *55*, 5929-5934.

Wood, P. (Eds.) (2006). *Understanding Immunology*. Essex: Pearson Education Limited.

Wurm, F. M. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. *Nature Biotechnology*, *22*, 1393–1398.

Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., & Davis, C. G. (2001). Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. *Critical Reviews in Oncology/Hematology*, *38*, 17-23.

Yang, X. Y., Jiang, H., Hartmann, W. K., Mitra, G., & Soman, G. (2003). Development of a quantitative antigen-specific cell-based ELISA for the 7G7/B6 monoclonal antibody directed toward IL-2R $\alpha$ . *Journal of Immunological Methods*, *277*, 87-100.

Yata, Y., Otsuji, E., Okamoto, K., Tsuruta, H., Kobayashi, S., Toma, A., et al. (2003). Decreased production of anti-mouse antibody after administration of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate to human. *Hepato-Gastroenterology*, *50*, 80-84.

Yazaki, P. J., Sherman, M. A., Shively, J. E., Ikle, D., Williams, L. E., Wong, J. Y. C., et al. (2004). Humanization of the anti-CEA T84.66 antibody based on crystal structure data. *Protein Engineering Design and Selection*, *17*, 481-489.

Yoshikawa, T., Nakanishi, F., Ogura, Y., Oi, D., Omasa, T., Katakura, Y., et al. (2001). Flow cytometry: An improved method for the selection of highly productive gene-amplified CHO cells using flow cytometry. *Biotechnology and Bioengineering*, *74*, 435-442.

Zafir-Lavie, I., Michaeli, Y., & Reiter, Y. (2007). Novel antibodies as anticancer agents. *Oncogene*, *26*, 3714-3733.

Zeng, Z. C., Tang, Z. Y., Liu, K. D., Lu, J. Z., Cai, X. J., & Xie, H. (1994). Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial <sup>131</sup>I-labeled Hepama-1 mAb. Preliminary results and discussion. *Cancer Immunology, Immunotherapy*, *39*, 332-336.

Zhang, F., Frost, A. R., Blundell, M. P., Bales, O., Antoniou, M. N., & Thrasher, A. J. (2010). A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. *Molecular Therapy*, *18*, 1640-1649.

Zhang, Q., Chen, G., Liu, X., & Qian, Q. (2007). Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. *Cell Research*, *17*, 89-99.

Zhu, J. (2011). Mammalian cell protein expression for biopharmaceutical production. *Biotechnology Advances*, doi: 10.1016/j.biotechadv.2011.08.022.

Ziegler, L. D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., et al. (1992). Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. *Journal of Clinical Oncology*, *10*, 1470-1478.